dc.creator |
Tshweu, Lesego |
|
dc.creator |
Katata, Lebogang |
|
dc.creator |
Kalombo, Lonji |
|
dc.creator |
Chiappetta, Diego |
|
dc.creator |
Hocht, Christian |
|
dc.creator |
Sosnik, Alejandro |
|
dc.creator |
Swai, Hulda |
|
dc.date |
2019-10-16T08:24:47Z |
|
dc.date |
2019-10-16T08:24:47Z |
|
dc.date |
2014-10-17 |
|
dc.date.accessioned |
2022-10-25T09:20:42Z |
|
dc.date.available |
2022-10-25T09:20:42Z |
|
dc.identifier |
1748-6963 |
|
dc.identifier |
24364871 |
|
dc.identifier |
https://doi.org/10.2217/nnm.13.167 |
|
dc.identifier |
http://dspace.nm-aist.ac.tz/handle/123456789/491 |
|
dc.identifier.uri |
http://hdl.handle.net/123456789/95159 |
|
dc.description |
Research Article published by NANOMEDICINEVOL. 9, NO. 12 |
|
dc.description |
Aim: To encapsulate efavirenz (EFV) within poly(epsilon-caprolactone) (PCL) nanoparticles (NPs) and compare the oral pharmacokinetics with that of EFV-loaded micelles and pure EFV NPs. Materials & methods: EFV-loaded PCL NPs were produced by a double-emulsion/spray-drying method. Results: NPs displayed a hydrodynamic diameter of 200–250 nm. The encapsulation efficiency was 86–93% and the mass recovery was above 60%. X-ray diffraction indicated that drug and PCL underwent amorphization during the spray-drying process. Encapsulation within NPs significantly increased the maximum concentration in plasma and the bioavailability. Conclusion: EFV-loaded PCL NPs represent a promising platform to develop scalable pharmaceuticals with improved (bio)pharmaceutic performance. |
|
dc.format |
application/pdf |
|
dc.language |
en |
|
dc.publisher |
NANOMEDICINE |
|
dc.subject |
HIV |
|
dc.subject |
Efavirenz |
|
dc.subject |
In vitro drug release |
|
dc.subject |
Oral bioavailability enhancement |
|
dc.subject |
Poly(epsilon-caprolactone) nanoparticle |
|
dc.subject |
Spray drying |
|
dc.title |
Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method. |
|
dc.type |
Article |
|